Omicron Variant: Effects on Treatments for COVID-19
Do COVID-19 treatments retain their efficacy against the SARS-CoV-2 omicron variant? Hear expert faculty discuss the use of direct-acting, small-molecule antiviral agents and monoclonal antibodies during the omicron era.
Decera Clinical Education Infectious Disease Podcast · Arthur Kim MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:
- Direct-acting, small-molecule antiviral agents such as molnupiravir, nirmatrelvir + ritonavir, and remdesivir
- Monoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimab
Presenter:
Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts
Review the downloadable slidesets at:
https://bit.ly/3FXc90w
https://bit.ly/32tp2BT
Link to full program:
https://bit.ly/3Ix8uZg
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.